Literature DB >> 21051638

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

Matthew Kraman1, Paul J Bambrough, James N Arnold, Edward W Roberts, Lukasz Magiera, James O Jones, Aarthi Gopinathan, David A Tuveson, Douglas T Fearon.   

Abstract

The stromal microenvironment of tumors, which is a mixture of hematopoietic and mesenchymal cells, suppresses immune control of tumor growth. A stromal cell type that was first identified in human cancers expresses fibroblast activation protein-α (FAP). We created a transgenic mouse in which FAP-expressing cells can be ablated. Depletion of FAP-expressing cells, which made up only 2% of all tumor cells in established Lewis lung carcinomas, caused rapid hypoxic necrosis of both cancer and stromal cells in immunogenic tumors by a process involving interferon-γ and tumor necrosis factor-α. Depleting FAP-expressing cells in a subcutaneous model of pancreatic ductal adenocarcinoma also permitted immunological control of growth. Therefore, FAP-expressing cells are a nonredundant, immune-suppressive component of the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051638     DOI: 10.1126/science.1195300

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  463 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

Review 2.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 3.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 4.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

5.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

6.  Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.

Authors:  Teresa S Kim; Michael J Cavnar; Noah A Cohen; Eric C Sorenson; Jonathan B Greer; Adrian M Seifert; Megan H Crawley; Benjamin L Green; Rachel Popow; Nagavarakishore Pillarsetty; Darren R Veach; Anson T Ku; Ferdinand Rossi; Peter Besmer; Cristina R Antonescu; Shan Zeng; Ronald P Dematteo
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

7.  Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.

Authors:  James N Arnold; Lukasz Magiera; Matthew Kraman; Douglas T Fearon
Journal:  Cancer Immunol Res       Date:  2013-11-18       Impact factor: 11.151

8.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

9.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.

Authors:  Céline A Blache; Edwin R Manuel; Teodora I Kaltcheva; Andrea N Wong; Joshua D I Ellenhorn; Bruce R Blazar; Don J Diamond
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

Review 10.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.